Autologous stem cell transplantation in mantle cell lymphoma: A report from the SFGM-TC

Annals of Hematology

Volumn 93, Issue 2, 2014, Pages 233-242

  Touzeau, Cyrille ^a,b   Leux, Christophe ^a   Bouabdallah, Reda ^c   Roussel, Murielle ^d   Delarue, Richard ^e   Bouabdallah, Krimo ^f   Thieblemont, Catherine ^g,h   Cacheux, Victoria ⁱ   Cartron, Guillaume ^j   Compain, Laetitia ^k   Gyan, Emmanuel ^l,m   Morschhauser, Franck ⁿ   Casasnovas, Olivier ^o   Moles, Marie Pierre ^p   Michallet, Anne Sophie ^q   Gressin, Remy ^r,s   Damaj, Gandhi ^t   Rose, Christian ^u   Sirvent, Anne ^v   Hermine, Olivier ^e   Mohty, Mohamad ^w   Milpied, Noel ^f   Le Gouill, Steven ^a,b   more..

^a NANTES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f University Hospital   (France)

^g SAINT LOUIS HOSPITAL   (France)

^h INSERM   (France)

ⁱ UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^j MONTPELLIER UNIVERSITY HOSPITAL   (France)

^k PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^l UNIVERSITY HOSPITAL OF TOURS   (France)

^m UNIVERSITÉ DE TOURS   (France)

ⁿ LILLE UNIVERSITY HOSPITAL   (France)

^o DIJON UNIVERSITY HOSPITAL   (France)

^p ANGERS UNIVERSITY HOSPITAL   (France)

^q University Hospital   (France)

^r GRENOBLE UNIVERSITY HOSPITAL   (France)

^s UNIV GRENOBLE ALPES   (France)

^t AMIENS UNIVERSITY HOSPITAL   (France)

^u Groupement Hospitalier de L'Institut Catholique Facultél Libre de Méldecine de Lille   (France)

^v UNIVERSITY HOSPITAL OF NICE   (France)

^w HÔPITAL SAINT ANTOINE   (France)

more..

Author keywords

Autologous stem cell transplantation; Mantle cell lymphoma; Prognostic factors

Indexed keywords

ADULT; AGE FACTORS; AGED; ANTHRACYCLINES; ANTIMETABOLITES, ANTINEOPLASTIC; AUTOGRAFTS; CYTARABINE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION CONDITIONING;

ANTHRACYCLINE; ANTINEOPLASTIC ANTIMETABOLITE; CYTARABINE;

ADULT; AGE; AGED; AUTOGRAFT; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

EID: 84895061381     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-013-1860-8     Document Type: Article

References (34)

1. Jares P, Campo E (2008) Advances in the understanding of mantle cell lymphoma. Br J Haematol 142:149-165. doi: 10.1111/j.1365-2141.2008.07124.x
2. Pérez-Galán P, Dreyling M, Wiestner A (2011) Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 117:26-38. doi: 10.1182/blood-2010-04-189977
3. Zhou Y, Wang H, Fang W et al (2008) Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 113:791-798. doi: 10.1002/cncr.23608
4. Harel S, Delarue R, Ribrag V et al (2011) Treatment of younger patients with mantle cell lymphoma. Semin Hematol 48:194-207. doi: 10.1053/j. seminhematol.2011.06.002
5. Kluin-Nelemans HC, Doorduijn JK (2011) Treatment of elderly patients with mantle cell lymphoma. Semin Hematol 48:208-213. doi: 10.1053/j.seminhematol. 2011.03.008
6. Herrmann A, Hoster E, Zwingers T et al (2009) Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 27:511-518. doi: 10.1200/JCO.2008.16.8435
7. Dreyling M, Lenz G, Hoster E et al (2005) Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 105:2677-2684. doi: 10.1182/blood-2004-10-3883
8. Damon LE, Johnson JL, Niedzwiecki D et al (2009) Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle cell lymphoma: CALGB 59909. J Clin Oncol 27:6101-6108. doi: 10.1200/JCO.2009.22.2554
9. Geisler CH, Kolstad A, Laurell A et al (2008) Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112:2687-2693. doi: 10.1182/blood-2008-03- 147025
10. Khouri IF, Romaguera J, Kantarjian H et al (1998) Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 16:3803-3809
11. Khouri IF, Saliba RM, Okoroji G-J et al (2003) Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score. Cancer 98:2630-2635. doi: 10.1002/cncr.11838
12. Lefrère F, Delmer A, Levy V et al (2004) Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study. Haematologica 89:1275-1276
13. Thieblemont C, Antal D, Lacotte-Thierry L et al (2005) Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma. Cancer 104:1434-1441. doi: 10.1002/cncr.21313
14. Vigouroux S, Gaillard F, Moreau P et al (2005) High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma. Haematologica 90:1580-1582
15. Gianni AM, Magni M, Martelli M et al (2003) Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 102:749-755. doi: 10.1182/blood-2002-08-2476
16. The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994. doi: 10.1056/NEJM199309303291402
17. Hoster E, Dreyling M, Klapper W et al (2008) A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111:558-565. doi: 10.1182/blood-2007-06-095331
18. Peterlin P, Leux C, Gastinne T et al (2012) Is ASCT with TBI superior to ASCT without TBI in mantle cell lymphoma patients? Transplantation 94:295-301. doi: 10.1097/TP.0b013e318256dcba
19. Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244
20. Budde LE, Guthrie KA, Till BG et al (2011) Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation. J Clin Oncol 29:3023-3029. doi: 10.1200/JCO.2010.33.7055
21. Lenz G, Dreyling M, Hoster E et al (2005) Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23:1984-1992. doi: 10.1200/JCO.2005.08.133
22. Schulz H, Bohlius JF, Trelle S et al (2007) Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 99:706-714. doi: 10.1093/jnci/djk152
23. Griffiths R, Mikhael J, Gleeson M et al (2011) Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. Blood 118:4808-4816. doi: 10.1182/blood-2011-04-348367
24. Hermine O, Hoster E, Walewski J et al (2012) Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL younger trial of the European mantle cell lymphoma network (MCL net). ASH Annu Meet Abstr 120:151
25. Pott C, Hoster E, Delfau-Larue M-H et al (2010) Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 115:3215-3223. doi: 10.1182/blood-2009-06-230250
26. Liu H, Johnson JL, Koval G et al (2012) Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909. Haematologica 97:579-585. doi: 10.3324/haematol.2011.050203
27. Pott C, Schrader C, Gesk S et al (2006) Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 107:2271-2278. doi: 10.1182/blood-2005-07-2845
28. Salles G, Seymour JF, Offner F et al (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377:42-51. doi: 10.1016/S0140-6736(10)62175-7
29. Van Oers MHJ, Klasa R, Marcus RE et al (2006) Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 108:3295-3301. doi: 10.1182/blood-2006-05-021113
30. Forstpointner R, Unterhalt M, Dreyling M et al (2006) Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108:4003-4008. doi: 10.1182/blood-2006-04-016725
31. Ghielmini M, Schmitz S-FH, Cogliatti S et al (2005) Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 23:705-711. doi: 10.1200/JCO.2005.04.164
32. Kluin-Nelemans HC, Hoster E, Hermine O et al (2012) Treatment of older patients with mantle cell lymphoma. N Engl J Med 367:520-531. doi: 10.1056/NEJMoa1200920
33. Le Gouill S, Callanan M, Macintyre E et al (2012) Clinical, metabolic and molecular responses after 4 courses of R-DHAP and after autologous stem cell transplantation for untreated mantle cell lymphoma patients included in the LyMa Trial, a Lysa Study. ASH Annu Meet Abstr 120:152
34. Andersen NS, Pedersen LB, Laurell A et al (2009) Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol 27:4365-4370. doi: 10.1200/JCO.2008.21. 3116